AltMountain

PFM Health Sciences, LP

San Francisco, CA · CRD 146747
Hedge fund manager

PFM Health Sciences, LP is an SEC-registered investment adviser based in San Francisco, CA that reports managing 2 hedge funds on Form ADV. It reports $1.3 billion in regulatory assets under management. Its private funds, of all types, hold $1.2 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +17.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +41.4% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$1.3 billionForm ADV Item 5.F
Gross assets of private funds
$1.2 billionAll private fund types, Form ADV
Hedge funds managed
24 private funds in total
Employees
17Form ADV Item 5.A
Registration
SEC-registered adviserCRD 146747
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+17.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+41.4%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$1.2 billion96 positions, 2026-06-30
$91$116$141Q3 2024Q1 2025Q3 2025Q1 202613F est. $141S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+24.4%+14.8%
Q1 2026-5.8%-4.6%
Q4 2025+18.5%+2.4%
Q3 2025+6.9%+7.8%
Q2 2025+1.8%+10.4%
Q1 2025+2.8%-4.5%
Q4 2024-11.9%+2.1%
Q3 2024+3.3%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 79 share positions ($936,374,650) reported by PFM Health Sciences, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Ascendis Pharma A/s5.57%
  • Axsome Therapeutics Inc.4.37%
  • United Therapeutics Corp Del4.01%
  • Tenet Healthcare Corp3.47%
  • Inhibrx Biosciences Inc3.42%
  • Eli Lilly & Co3.10%
  • Neurocrine Biosciences Inc3.10%
  • Indivior Pharmaceuticals Inc2.84%
  • State STR SPDR S&P 500 ETF T2.64%
  • Bridgebio Pharma Inc2.57%
StockValue% of 13F portfolioSharesShares vs prior quarter
Ascendis Pharma A/s$52,142,9965.57%228,868-1.85%
Axsome Therapeutics Inc.$40,953,3884.37%222,102+1.14%
United Therapeutics Corp Del$37,522,0894.01%69,243+38.51%
Tenet Healthcare Corp$32,531,2553.47%127,294+0.57%
Inhibrx Biosciences Inc$32,058,7263.42%320,331+3.87%
Eli Lilly & Co$29,014,9383.10%25,076-36.13%
Neurocrine Biosciences Inc$28,983,0183.10%204,336-4.25%
Indivior Pharmaceuticals Inc$26,595,8242.84%741,864+84.91%
State STR SPDR S&P 500 ETF T$24,725,2272.64%32,421New
Bridgebio Pharma Inc$24,054,5062.57%365,570+44.29%
Thermo Fisher Scientific Inc$21,591,4742.31%31,985+12.24%
Revolution Medicines Inc$20,958,8932.24%102,109-28.71%
Jazz Pharmaceuticals PLC$20,589,3052.20%88,931-44.68%
Humana Inc$19,489,8322.08%51,078-45.88%
Waters Corp$19,296,2512.06%43,916-26.59%
Unitedhealth Group Inc$18,231,3951.95%49,666-43.74%
Abbott Laboratories$17,436,9721.86%176,434+114.56%
Cytokinetics Inc$17,058,9581.82%258,822+35.02%
Amneal Pharmaceuticals Inc$16,573,0251.77%822,891+71.18%
Oscar Health Inc$15,414,9731.65%499,837-3.70%
Conmed Corp$14,989,8931.60%324,246New
Madrigal Pharmaceuticals Inc$14,552,3491.55%28,876-1.49%
Teleflex Incorporated$14,513,6431.55%116,072+45.62%
Teva Pharmaceutical Inds LTD$14,067,9401.50%355,251New
Zimmer Biomet Holdings Inc$13,806,4031.47%155,425New
Glaukos Corp$13,188,0691.41%80,322New
Edwards Lifesciences Corp$13,105,2751.40%151,822-39.38%
Definium Therapeutics Inc$12,753,9441.36%335,101+34.57%
Veeva SYS Inc$11,326,3711.21%39,679New
Genmab A/s$11,190,4981.20%313,679New
Exelixis Inc$11,027,1651.18%188,789New
Irhythm Holdings Inc$10,978,7601.17%96,593+48.16%
Praxis Precision Medicines I$10,625,2351.13%36,484-5.42%
Centene Corp Del$10,532,7571.12%169,555-31.87%
Kodiak Sciences Inc$10,385,0561.11%109,547+13.34%
Takeda Pharmaceutical Co LTD$10,315,5671.10%567,101+27.68%
Eupraxia Pharmaceuticals Inc$10,264,0811.10%1,127,921-6.83%
Danaher Corp Del$10,116,6381.08%45,663New
Arrowhead Pharmaceuticals In$9,819,5941.05%150,032+13.95%
Integra Lifesciences Hldgs C$9,425,8111.01%578,981+66.02%
Belite Bio Inc$9,353,3461.00%55,078+58.26%
Icon Pub LTD Co$8,542,6770.91%50,254-63.18%
Ionis Pharmaceuticals Inc$8,523,9080.91%190,905New
Amylyx Pharmaceuticals Inc$8,218,8290.88%282,434+96.54%
Elanco Animal Health Inc$7,723,3410.82%344,946+99.98%
Bio Rad Labs Inc$7,661,0920.82%20,283+44.93%
Celldex Therapeutics Inc New$7,642,7640.82%235,815-31.20%
Guardant Health Inc$7,564,4260.81%42,411+15.56%
Brightspring Health Svcs Inc$7,241,4700.77%127,603-10.08%
Charles Riv Labs Intl Inc$7,182,6080.77%24,347+29.87%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 22 new positions, 39 sold out, 27 increased, 28 reduced and 2 unchanged.

Number of positions (a count, not dollars)

  • New positions22
  • Increased27
  • Unchanged2
  • Reduced28
  • Sold out39

New positions

StockValueShares
State STR SPDR S&P 500 ETF T$24,725,22732,421
Conmed Corp$14,989,893324,246
Teva Pharmaceutical Inds LTD$14,067,940355,251
Zimmer Biomet Holdings Inc$13,806,403155,425
Glaukos Corp$13,188,06980,322
Veeva SYS Inc$11,326,37139,679
Genmab A/s$11,190,498313,679
Exelixis Inc$11,027,165188,789
Danaher Corp Del$10,116,63845,663
Ionis Pharmaceuticals Inc$8,523,908190,905
Doximity Inc$6,409,459226,163
Ge Healthcare Technologies I$5,463,23283,574
Minimed Group Inc$3,984,789204,663
Dexcom Inc$3,977,27946,092
Freenome Inc$3,650,693231,790
Damora Therapeutics Inc Com SHS$3,072,023144,362
Twist Bioscience Corp$2,903,62415,026
Iqvia Hldgs Inc$2,879,38410,710
Invesco QQQ TR$2,746,7663,713
10X Genomics Inc$1,841,17520,376

Sold out

StockValue at Jun 30, 2026Shares held then
Penumbra Inc$19,014,78160,221
Stryker Corporation$17,831,59356,637
Mettler Toledo International$17,047,09313,344
Merck & Co Inc$16,334,663127,118
Lantheus Hldgs Inc$16,241,949146,403
Cooper Cos Inc$15,840,022220,890
Acadia Healthcare Company In$15,501,301524,934
Oruka Therapeutics Inc$15,115,375158,825
CVS Health Corp$14,219,927137,457
Merit Med SYS Inc$13,662,615197,038
Novo-nordisk A S$12,704,867265,016
Integer Hldgs Corp$11,837,218126,669
Gilead Sciences Inc$11,479,00090,858
Schein Henry Inc$11,227,009134,423
Tango Therapeutics Inc$10,192,229326,047
Roivant Sciences LTD$9,484,803268,008
CG Oncology Inc$9,114,720128,286
Arcutis Biotherapeutics Inc$6,347,049242,069
Illumina Inc$6,161,08335,040
Meiragtx Hldgs PLC$6,150,914455,286

Largest increases

StockChange in sharesChangeValue nowShares now
Indivior Pharmaceuticals Inc+340,656+84.91%$26,595,824741,864
United Therapeutics Corp Del+19,252+38.51%$37,522,08969,243
Abbott Laboratories+94,204+114.56%$17,436,972176,434
Bridgebio Pharma Inc+112,212+44.29%$24,054,506365,570
Amneal Pharmaceuticals Inc+342,176+71.18%$16,573,025822,891
Teleflex Incorporated+36,364+45.62%$14,513,643116,072
Cytokinetics Inc+67,136+35.02%$17,058,958258,822
Omnicell Com+119,403+243.48%$5,735,484168,443
Amylyx Pharmaceuticals Inc+138,734+96.54%$8,218,829282,434
Elanco Animal Health Inc+172,457+99.98%$7,723,341344,946
Integra Lifesciences Hldgs C+230,235+66.02%$9,425,811578,981
Irhythm Holdings Inc+31,397+48.16%$10,978,76096,593
Belite Bio Inc+20,275+58.26%$9,353,34655,078
Definium Therapeutics Inc+86,081+34.57%$12,753,944335,101
Bio Rad Labs Inc+6,288+44.93%$7,661,09220,283
Thermo Fisher Scientific Inc+3,489+12.24%$21,591,47431,985
Takeda Pharmaceutical Co LTD+122,928+27.68%$10,315,567567,101
Omada Health Inc+95,854+83.76%$4,376,260210,296
Charles Riv Labs Intl Inc+5,600+29.87%$7,182,60824,347
Kodiak Sciences Inc+12,890+13.34%$10,385,056109,547

Largest reductions

StockChange in sharesChangeValue nowShares now
Jazz Pharmaceuticals PLC-71,837-44.68%$20,589,30588,931
Humana Inc-43,297-45.88%$19,489,83251,078
Eli Lilly & Co-14,182-36.13%$29,014,93825,076
Icon Pub LTD Co-86,228-63.18%$8,542,67750,254
Unitedhealth Group Inc-38,610-43.74%$18,231,39549,666
Edwards Lifesciences Corp-98,631-39.38%$13,105,275151,822
Revolution Medicines Inc-41,113-28.71%$20,958,893102,109
Waters Corp-15,909-26.59%$19,296,25143,916
Dianthus Therapeutics Inc-59,923-49.43%$5,397,37761,299
Centene Corp Del-79,312-31.87%$10,532,757169,555
Rhythm Pharmaceuticals Inc-45,563-44.87%$5,330,80255,987
Celldex Therapeutics Inc New-106,936-31.20%$7,642,764235,815
Vera Therapeutics Inc-80,316-35.81%$4,648,888143,973
Hinge Health Inc-24,225-29.24%$5,701,66758,635
Viking Therapeutics Inc-66,958-26.22%$6,140,927188,372
Abivax SA-19,358-44.74%$2,367,17223,906
West Pharmaceutical Svsc Inc-4,424-21.34%$6,046,72516,309
Cullinan Therapeutics Inc-87,727-45.59%$1,607,375104,715
Neurocrine Biosciences Inc-9,071-4.25%$28,983,018204,336
Oculis Holding AG-108,747-24.94%$3,056,935327,295

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Outset Medical, Inc.13G amendment2.9%530,796Feb 17, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Feb 17, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private investment funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (6)

Fund
Gross assets
Minimum
Owners
Adviser
PFM Healthcare Master Fund, L.P.
Cayman IslandsHedge fund
Gross assets$2.2B
MinimumNone set
Owners425
AdviserPFM Health Sciences, LP
PFM Biotech Opportunities LP
Delaware, United StatesPrivate equity fund
Gross assets$109M
Minimum$5.0M
Owners73
AdviserPFM Health Sciences, LP
PFM Healthcare Growth Equity Fund I, LP
Delaware, United StatesPrivate equity fund
Gross assets$56.4M
Minimum$5.0M
Owners46
AdviserPFM Health Sciences, LP
Partner Investments, L.P.
Delaware, United StatesHedge fund
Gross assets$24.2M
Minimum$10K
Owners70
AdviserPFM Health Sciences, LP
PFM Songbird, LP
Delaware, United StatesPrivate equity fund
Gross assets$3.7M
Minimum$10K
Owners10
AdviserPFM Health Sciences, LP
PFM Meta, LP
Delaware, United StatesPrivate equity fund
Gross assets$3.7M
Minimum$10K
Owners10
AdviserPFM Health Sciences, LP

As reported in the adviser's Form ADV filed Jun 24, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​‌⁠